| [1] |
Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review[J]. Endocrinology, 163(1): bqab203.
|
| [2] |
国务院联防联控机制综合组. 关于印发新型冠状病毒感染防控方案(第十版)的通知[EB/OL]. 2023. http://www.gov.cn/xinwen/202301/07/content_5735448.htm.
|
| [3] |
宁光. 糖皮质激素类药物临床应用指导原则[J]. 中华内分泌代谢杂志, 2012, 28(2):171-202.
|
| [4] |
Arlt W, Baldeweg SE, Pearce SH, et al. L. Endocrinology in the time of COVID-19: management of adrenal insufficiency[J]. Eur J Endocrinol, 183(1): G25-G32.
doi: 10.1530/EJE-20-0361
URL
|
| [5] |
中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 727-736.
|
| [6] |
Tzoulis P, Waung JA, Bagkeris E, et al. Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(6): 1637-1648.
doi: 10.1210/clinem/dgab107
pmid: 33624101
|
| [7] |
Tzoulis P, Grossman AB, Baldeweg SE, et al. Management of endocrine disease: dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management[J]. Eur J Endocrinol, 2021, 185(4): R103-R111.
doi: 10.1530/EJE-21-0281
URL
|
| [8] |
Atila C, Sailer CO, Bassetti S, et al. Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls[J]. Eur J Endocrinol, 2021, 184(3): 409-418.
doi: 10.1530/EJE-20-1374
pmid: 33449918
|
| [9] |
中华医学会内分泌学分会. 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 737-750.
|
| [10] |
Raghavan D, Tan AR, Story ES, et al. Management changes for patients with endocrine-related cancers in the COVID-19 pandemic[J]. Endocr Relat Cancer, 2020, 27(9): R357-R374.
doi: 10.1530/ERC-20-0229
URL
|
| [11] |
National Institute of Health. Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications[EB/OL]. 2022. https://www.covid19tre-atmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/.
|
| [12] |
Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19[J]. Science, 2021, 374(6575): 1586-1593.
doi: 10.1126/science.abl4784
URL
|
